Manufacturing, latest filing in August 2025

Above Food Ingredients Inc.

Above Food Ingredients Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-19. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Above Food Ingredients Inc., with its principal executive office as 2305 Victoria Avenue, Suite 001, Regina, Saskatchewan (SCHEDULE 13G, 2025-08-19).

5.08%. The percent of class is based on the sum of (i) 51,191,848 shares of common stock outstanding as of May 2, 2025, as reported by Issuer on its Form 6-K filed with the Securities and Exchange Commission on May 23, 2025, plus (ii) the 2,738,574 shares of common stock owned by Arcadia.Arcadia Biosciences, Inc., SCHEDULE 13G, 2025-08-19

Swipe the table sideways to see every column.

Azek Co Inc

Azek Co Inc has 2 Schedule 13D or 13G filings on record since 2025-07-07. 1 holder's latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Azek Co Inc, with its principal executive office as 1330 W FULTON STREET, #350, CHICAGO, IL 60607 (SCHEDULE 13G/A, 2025-08-06).

Swipe the table sideways to see every column.

Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Bellicum Pharmaceuticals Inc, with its principal executive office as 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX 77098 (SCHEDULE 13G, 2025-08-14).

Swipe the table sideways to see every column.

BioLineRx Ltd.

BioLineRx Ltd. has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of ordinary shares, par value nis 0.10 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names BioLineRx Ltd., with its principal executive office as 2 HAMA-AYAN STREET, MODI-IN TECHNOLOGY PARK, MODI-IN (SCHEDULE 13G, 2025-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Captivision Inc.

Captivision Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Captivision Inc., with its principal executive office as 298-42 CHUNG-BUK CHUNGANG-RO CHUNG-BUK, PYEONG-TAEK, GYOUNGGI (SCHEDULE 13G, 2025-08-14).

Swipe the table sideways to see every column.

CEL-SCI Corporation

CEL-SCI Corporation has 1 Schedule 13D or 13G filing on record since 2025-08-29. 1 holder's latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names CEL-SCI Corporation, with its principal executive office as 8229 Boone Boulevard, Suite 802, Vienna, VA 22182 (SCHEDULE 13G, 2025-08-29).

Swipe the table sideways to see every column.

CONTRAFECT Corp

CONTRAFECT Corp has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names CONTRAFECT Corp, with its principal executive office as 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY 10701 (SCHEDULE 13G, 2025-08-14).

Swipe the table sideways to see every column.

Delek US Holdings, Inc

Delek US Holdings, Inc has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of ion asset management ltd.. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Delek US Holdings, Inc, with its principal executive office as 310 SEVEN SPRINGS WAY, BRENTWOOD, TN 37027 (SCHEDULE 13G/A, 2025-08-14).

Swipe the table sideways to see every column.

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Eagle Pharmaceuticals, Inc., with its principal executive office as 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ 07677 (SCHEDULE 13G/A, 2025-08-14).

Swipe the table sideways to see every column.

Healthy Extracts Inc.

Healthy Extracts Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-22. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Healthy Extracts Inc. by CUSIP 42227D209 and gives its principal executive office as 7375 COMMERCIAL WAY, SUITE 125, HENDERSON, NV 89011 (SCHEDULE 13D, 2025-08-22).

Assets and equity of Gummy USA, LLC merger with HYEX.Swanson Donald William, SCHEDULE 13D, 2025-08-22

Swanson Donald William

The securities were acquired in the Healthy Extracts Inc and Gummy USA, LLC merger.Item 4 of the SCHEDULE 13D filed 2025-08-22

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Peraso Inc.

Peraso Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Peraso Inc. by CUSIP 71360T200 and gives its principal executive office as 2033 Gateway Place, Suite 500, San Jose, CA 95110 (SCHEDULE 13D, 2026-11-04).

See Item 11 on the cover pages hereto.Richard Abbe, SCHEDULE 13G/A, 2025-08-14

On October 26, 2026, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with Nant Capital, LLC (the "Purchaser"), pursuant to which the Issuer agreed to issue and sell to the Purchaser shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), warrants to purchase Common Stock (the "Common Warrants") and/or pre-funded Common Stock purchase warrants (the "Pre-Funded Warrants," and together with the Common Warrants, the "Warrants") (the "PIPE").Nant Capital, LLC, SCHEDULE 13D, 2026-11-04

Nant Capital, LLC

The information set forth in Item 3 of this Schedule is incorporated herein by reference. The Reporting Person acquired the shares of Common Stock, Pre-Funded Warrants and Common Warrants for investment purposes. From and after the Closing, for so long as the Purchaser and its affiliates beneficially own sixteen and seven-tenths percent (16.7%) or more of the Issuer's outstanding Common Stock (including, solely for this purpose, shares of Common Stock issuable upon exercise of the Pre-Funded Warrants), the Purchaser will have the right, but not the obligation, to designate two (2) individuals for appointment to the Issuer's board of directors, one of whom shall be the Reporting Person so long as the Reporting Person is reasonably available, and for so long as the Purchaser and its affiliates beneficially own five percent (5%) or more of the Issuer's outstanding Common Stock (calculated on the same basis), the Purchaser will have the right, but not the obligation, to designate one (1) individual for appointment to the Issuer's board of directors, in each case subject to compliance with applicable Nasdaq rules. The Issuer has agreed to include the Purchaser's designees in the board's slate of nominees at each applicable meeting of stockholders and to use its reasonable best efforts to cause their election, and each designee is required to tender his or her resignation if the Purchaser's ownership falls below the applicable threshold. These rights are personal to the …The first part of Item 4 of the SCHEDULE 13D filed 2026-11-04; the filing has the rest

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

PlayAGS, Inc.

PlayAGS, Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names PlayAGS, Inc., with its principal executive office as 6775 S. Edmond St., Suite #300, Las Vegas, NV 89118 (SCHEDULE 13G/A, 2025-08-14).

Swipe the table sideways to see every column.

Purple Innovation, Inc.

Purple Innovation, Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-14. 1 holder's latest filing reports 5% or more of class a common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Purple Innovation, Inc., with its principal executive office as 4100 N. CHAPEL RIDGE RD, SUITE 200, LEHI, UT 84043 (SCHEDULE 13G, 2025-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Retractable Technologies, Inc.

Retractable Technologies, Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-29. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Retractable Technologies, Inc. by CUSIP 76129W105 and gives its principal executive office as 511 Lobo Lane, Little Elm, TX 75068-0009 (SCHEDULE 13D/A, 2025-08-29).

Thomas J. Shaw

As reported in other public filings for the Reporting Person and Issuer, the Reporting Person entered into a written plan for the purchase of Retractable Technologies, Inc. common stock intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) on August 22, 2024. In accordance with the plan, trading began November 20, 2025 and may continue through November 19, 2025 if not earlier terminated.Item 4 of the SCHEDULE 13D/A filed 2025-08-29

Swipe the table sideways to see every column.

SuperCom Ltd

SuperCom Ltd has 2 Schedule 13D or 13G filings on record since 2025-08-05. 1 holder's latest filing reports 5% or more of ordinary shares, nis 50 par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names SuperCom Ltd, with its principal executive office as 1 ARIE SHENKAR STREET, HERTZLIYA (SCHEDULE 13G/A, 2025-08-14).

Swipe the table sideways to see every column.

Triumph Group Inc

Triumph Group Inc has 3 Schedule 13D or 13G filings on record since 2025-08-11. 1 holder's latest filing reports 5% or more of common stock, par value $.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing names Triumph Group Inc, with its principal executive office as 555 E LANCASTER AVENUE, SUITE 400, RADNOR (SCHEDULE 13G/A, 2025-08-14).

Swipe the table sideways to see every column.